News

Article

Knowledge of PrEP Guidelines Leads to Higher Likelihood of Prescribing PrEP to Young Adults, Adolescents

Study investigators found that health care professionals who were assigned male at birth and practiced in the Western region of the United States were more likely to prescribe PrEP to this high-risk population.

Despite pre-exposure prophylaxis (PrEP) expanding recommended ages for prevention of HIV in high-risk populations, adolescents and young adults have demonstrated a slower uptake of PrEP. Adolescents and young adults between ages 13 and 24 years are still largely not being prescribed PrEP, even though this high-risk group accounts for approximately 20% of new HIV infections.

Man holding oral PrEP

Adolescents and young adults between ages 13 and 24 years are still largely not being prescribed PrEP, even though this high-risk group accounts for approximately 20% of new HIV infections. Image credit: samael334 | stock.adobe.com

A recent study published in Nature analyzes the characteristics of primary care physicians to see how demographic, clinical care, and implementation factors influence the prescribing of PrEP to adolescents and young adults. Although prior research has evaluated the prescribing patterns of PrEP in certain populations, the factors that influence prescribing are examined less frequently, according to the investigators.

The investigators used the Theoretical Domains Framework, a commonly used approach in research to evaluate physicians’ evidence-based practices. A prior study utilized this framework to determine physician intent to prescribe PrEP in adolescents.

The study authors determined that providers who were assigned male at birth, practiced in the Western region of the United States, and had more knowledge about PrEP prescribing guidelines were more likely to prescribe PrEP to adolescents and young adults. Further, differences in prescribing rates between genders could be due to male adolescents—who are more affected by HIV—seeking male providers, differences in adoption of new treatments by male and female providers, or proportion of male and female providers across different practices.

In addition, the research showed that geographic differences could be a result of the availability of providers who specialize in PrEP, or differences in state policies which allow minors to access HIV-related care without the permission of a parent or guardian. The authors note that additional research that explores these geographic differences could be beneficial in determining what influences the differences.

The findings could also indicate a potential value of programs that educate providers on PrEP and its prescribing guidelines. Further, geographic differences in prescribing behaviors suggest that changes to laws that allow adolescents to seek care related to HIV without parental consent could further improve the uptake of PrEP in this high-risk group.

“Most PrEP research focuses on providers’ intentions to prescribe, while we looked at the determinants of prior prescribing PrEP, finding 2 main points,” said study author Christopher Owens, PhD, assistant professor in the department of health behavior at the Texas A&M University School of Public Health, in a press release. “First, knowledge is important in better understanding providers’ behaviors in delivering this HIV preventive evidence-based practice. Also, structural factors like laws and access to care—that vary widely between states and regions—might be important in mediating or moderating providers’ prescription habits.”

Reference

Texas A&M University. What factors influence PrEP prescribing behavior in health care providers? News release. November 14, 2023. Accessed November 14, 2023. https://www.eurekalert.org/news-releases/1008027

Related Videos
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards